london

AKESOgen and London Genetics International alliance to enhance drug development

 

 

AKESOgen and London Genetics International alliance to enhance drug development through pharmacogenetics and related services

Norcross, GA, US and London, UK – March 29th 2012 – AKESOgen, the genomics and biorepository services company, and London Genetics International, an expert in the use of pharmacogenetics in drug discovery and development, today announced a strategic alliance to offer the biopharmaceutical industry innovative pharmacogenetics solutions to advance personalized medicine and provide trans Atlantic services. The alliance combines world-class expertise and American-European infrastructure to support biopharma drug development. Financial terms were not disclosed.

“Our expertise in pharmacogenetic strategy development combined with a professional genomics services company that operates to CLIA standards will make this strategic alliance beneficial to both companies as it will increase our scope of possible services into the Americas with highly qualified and service oriented scientists. This represents our first deal following our acquisition by LSBC which from our side was a critical step for making this happen” said Elizabeth Foot, VP Personalised Medicine and Nutrition, London Genetics International.

Under the alliance, AKESOgen and London Genetics International will collaborate to help biopharma companies take advantage of pharmacogenetic solutions, including novel biomarker and assay development services. By providing biopharma companies strategic advice on the application of pharmacogenetics and innovative pharmacogenetics solutions, AKESOgen and London Genetics can help customers access additional resources and speed the delivery of targeted treatments.

Notes to Editors:

Contact details

Mark Bouzyk, PhD, Chief Scientific Officer, AKESOgen, Inc.
T: +1 855 661 8920 (Toll Free)
C: +1 404 771 8667
E: mbouzyk@akesogen.com

Elizabeth Foot, DPhil, London Genetics International
C: +44 (0) 7540 722236
E: efoot@londongenetics.com

About AKESOgen, Inc.

AKESOgen is an integrated genomics and pharmacogenetics company providing biorepository services and high-throughput, biomarker profiling and genomics analysis utilizing different types of markers (e.g. DNA, mRNA, miRNA, methylation) for the R&D market in to CLIA standards. A private company based in Atlanta, GA, AKESOgen is a genomics contract research organization that services the academic, pharmaceutical, biotechnology, clinical testing and agricultural sectors. AKESOgen provides expertise in biobanking, assay development and all ancillary services in a purpose-built facility.

www.akesogen.com

About London Genetics International

London Genetics International has extensive experience and expertise in the fields of personalized medicine and nutrition. The Company provides strategic advice on the application of these approaches to optimize clinical development and commercialization of stratified medicines, as well as for the development of novel food products and stratified nutritional strategies. London Genetics fosters open innovation approaches and has established relationships with major academic sites within London, Central Europe and the USA. It works at the academic-industry interface to facilitate partnerships between industry and academic centers of excellence. These centers are at the forefront of research in genetics, translation medicine and nutrition with access to large patient cohorts and samples across a breadth of therapeutic areas, as well as cutting edge technologies.

London Genetics International Ltd is the trading name for LSBC (London) Ltd.

www.londongeneticslimited.com

Share this Facebooktwittergoogle_plusredditlinkedinmailFacebooktwittergoogle_plusredditlinkedinmail

CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1-98 trial

CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1-98 trial.

Regan MM, Leyland-Jones B, Bouzyk M, Pagani O, Tang W, Kammler R, Dell’orto P, Biasi MO, Thürlimann B, Lyng MB, Ditzel HJ, Neven P, Debled M, Maibach R, Price KN, Gelber RD, Coates AS, Goldhirsch A, Rae JM, Viale G; Breast International Group (BIG) 1-98 Collaborative Group.

J Natl Cancer Inst. 2012 Mar 21;104(6):441-51. doi: 10.1093/jnci/djs125. Epub 2012 Mar 6.

PMID: 22395644 [PubMed – indexed for MEDLINE] Free PMC Article

Share this Facebooktwittergoogle_plusredditlinkedinmailFacebooktwittergoogle_plusredditlinkedinmail